XOMA (XOMA) Rating Reiterated by Wedbush

XOMA (NASDAQ:XOMA)‘s stock had its “outperform” rating restated by Wedbush in a research note issued on Monday, September 17th.

Other analysts have also recently issued research reports about the company. TheStreet raised XOMA from a “d” rating to a “c-” rating in a research report on Tuesday, June 12th. S&P Equity Research lowered their price objective on XOMA from $18.74 to $16.26 in a research report on Tuesday, August 14th. Zacks Investment Research cut XOMA from a “hold” rating to a “sell” rating in a research report on Saturday, August 11th. Finally, ValuEngine lowered XOMA from a “hold” rating to a “sell” rating in a research note on Friday, September 7th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $31.32.

NASDAQ:XOMA traded down $0.41 during midday trading on Monday, hitting $15.30. The stock had a trading volume of 126,891 shares, compared to its average volume of 131,963. XOMA has a one year low of $14.61 and a one year high of $37.25. The stock has a market cap of $147.36 million, a P/E ratio of 15.61 and a beta of 2.51. The company has a quick ratio of 12.46, a current ratio of 12.46 and a debt-to-equity ratio of 3.06.

XOMA (NASDAQ:XOMA) last announced its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $2.26 million for the quarter, compared to the consensus estimate of $4.57 million. XOMA had a net margin of 43.55% and a return on equity of 379.39%. On average, sell-side analysts anticipate that XOMA will post -1.14 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XOMA. Allianz Asset Management GmbH grew its position in shares of XOMA by 32.7% during the 1st quarter. Allianz Asset Management GmbH now owns 12,245 shares of the biotechnology company’s stock valued at $248,000 after acquiring an additional 3,020 shares during the period. ClariVest Asset Management LLC grew its position in shares of XOMA by 25.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 23,500 shares of the biotechnology company’s stock valued at $490,000 after acquiring an additional 4,700 shares during the period. Dynamic Technology Lab Private Ltd grew its position in shares of XOMA by 57.6% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 20,112 shares of the biotechnology company’s stock valued at $420,000 after acquiring an additional 7,349 shares during the period. Spark Investment Management LLC grew its position in shares of XOMA by 16.6% during the 2nd quarter. Spark Investment Management LLC now owns 52,100 shares of the biotechnology company’s stock valued at $1,087,000 after acquiring an additional 7,400 shares during the period. Finally, Alps Advisors Inc. boosted its holdings in XOMA by 82.6% in the 2nd quarter. Alps Advisors Inc. now owns 19,946 shares of the biotechnology company’s stock worth $542,000 after buying an additional 9,024 shares during the last quarter. Institutional investors and hedge funds own 43.60% of the company’s stock.

About XOMA

XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.

Read More: Return on Equity (ROE)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply